By Sukriti Gupta and Medha Singh (Reuters) -European shares fell on Tuesday, dragged down by heavyweight Novo Nordisk, while ...

Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several ...

Even though the stock is down notably from the peak price it hit last year, it's still doing far better than in the pre-approval days. Competitors are biting at its heels in the weight loss segment, ...

Stocks in drugmakers sold off globally after President Trump said tariffs on pharmaceutical imports will be unveiled shortly, ...

(Reuters) -European shares fell on Tuesday as heavyweight Novo Nordisk slumped, while U.S. President Donald Trump's vocal ...

Novo Nordisk A/S slumped after a pill from rival Eli Lilly & Co. helped patients shed weight and control blood sugar about as ...

Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results ...

Column chart showing Novo Nordisk shares monthly percentage change ... fund manager at healthcare-focused Bellevue Asset Management in Switzerland, which holds Novo shares, said he and other ...

Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

Switzerland's Roche and France's Sanofi dropped 5.7% and 6.4% respectively in Europe. Japan's Daiichi Sankyo and Takeda Pharmaceutical closed 6% and 4.7% lower, respectively. The drug sector was ...